Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of ABBV-519 in systemic lupus erythematosus or rheumatoid arthritis
jRCT2031260449Phase 1Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 1, open-label trial of ABBV-519 in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Change from baseline in B cells in blood, Cmax of ABBV-519 and 5 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ABBV-519
03
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2031260449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260449.